Remdesivir in covid-19
- PMID: 32321732
- DOI: 10.1136/bmj.m1610
Remdesivir in covid-19
Conflict of interest statement
Competing interests: We have read and understood BMJ policy on declaration of interests and declare that JKA is a member of the Centre for Evidence-Based Medicine in Oxford, which jointly runs the EvidenceLive Conference with the BMJ and the overdiagnosis conference with some international partners, which are based on a non-profit model. He is an associate editor of BMJ Evidence Based Medicine and was until recently vice president publications for the British Pharmacological Society. REF was until recently a member of the Birmingham, Sandwell and Solihull Area prescribing committee, is a series editor of The BMJ’s Therapeutic Series, and has an honorary position at University College London.
Comment on
-
Compassionate Use of Remdesivir for Patients with Severe Covid-19.N Engl J Med. 2020 Jun 11;382(24):2327-2336. doi: 10.1056/NEJMoa2007016. Epub 2020 Apr 10. N Engl J Med. 2020. PMID: 32275812 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources